Archives: Press Releases
Alivexis to present ModBind™ at MACNICA booth at the AI EXPO Tokyo
News -
28 October, 2024 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S.Roy Kimura, “Alivexis”), a preclinical stage technology-driven drug discovery company, will present ModBind™, our drug discovery platform at MACNICA, Inc. booth at the 5th AI EXPO Tokyo held at Makuhari Messe, Tokyo on November 20th-22nd, 2024. The AI EXPO Tokyo is the largest trade show about AI in ...continuedCathepsin C Inhibitor Proved Effective in the Treatment of Vasculitis～Expectations for a Novel Therapeutic Agent for ANCA-Associated Vasculitis～
News -
23 August, 2024 -
Alivexis, Inc. and Hokkaido University today announced the publication of a joint research article entitled “Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders,” published in Nature Communications on August 22, 2024. The research, led by Assistant Professor Yuka Nishibata, Dr. Sakiko Masuda, and Professor Akihiro Ishizu of the Graduate School ...continuedMelodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A
News -
21 June, 2024 -
Alivexis, Inc. (headquartered in Tokyo, Japan, “Alivexis”) and Melodia Therapeutics AG (headquartered in Basel, Switzerland, “Melodia”), a company established by Forty51 Ventures, announced today that they have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis’ MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential. MDI-0151 is an innovative ...continuedAlivexis with Astellas Pharma Inc. to Collaborate on Novel Drug Target
News -
17 June, 2024 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura) is pleased to announce that the Company has entered into a Research Collaboration Agreement with Astellas Pharma Inc. (“Astellas”) to identify small molecule compounds for a new drug target selected by Astellas, utilizing Alivexis’ drug discovery platform ModBind™ and other technologies. The collaboration aims to ...continuedJoint Research on Novel Anti-Allergic Disease Drug Candidate Published by Alivexis, Inc. and University of Yamanashi
News -
11 April, 2024 -
Alivexis, Inc., and the University of Yamanashi announce the publication of a joint research article entitled “A highly selective KIT inhibitor MOD000001 suppresses IgE-mediated mast cell activation”, published in JACI: Global, an open-access online journal from the American Association of Allergy, Asthma and Immunology (AAAAI). The research, led by Associate Professor Yuki Nakamura and ...continuedModulus Discovery, Inc. to Change Its Name to Alivexis, Inc. on March 11, 2024
News -
11 March, 2024 -
Modulus Discovery, Inc (Headquartered in Chiyoda-ku, Tokyo; CEO S. Roy Kimura) is pleased to announce that, effective March 11, 2024, the Company has changed its name to Alivexis, Inc. 【Details】 ● New company name: Alivexis, Inc.（URL：https://alivexis.com） ● Date of change: March 11, 2024 *Please note that this change is limited to the company name; there will be ...continuedModulus Discovery, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
News -
09 January, 2024 -
Modulus Discovery, Inc. (“Modulus”), a preclinical stage technology-driven drug discovery company, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The J.P. Morgan Healthcare Conference, the largest and most informative healthcare investment symposium in the industry, will be held in San Francisco on January 8-11, 2024. Roy Kimura, Modulus co-founder and CEO, will present ...continuedPeptiDream and Modulus Announce Nomination of First Clinical Development Candidate from Strategic Partnership
News -
03 August, 2023 -
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) and Modulus Discovery, Inc., a privately held Tokyo-based drug discovery company (CEO: S. Roy Kimura, hereinafter “Modulus”) today announced the nomination of the first clinical development candidate arising from the companies’ strategic drug discovery partnership. Under the companies’ ...continuedModulus Discovery has been selected as a “J-Startup” company by the Ministry of Economy, Trade and Industry of Japan
News -
06 April, 2023 -
Today, Modulus Discovery, Inc. (“the Company”) announced that the Company has been selected as a “J-Startup” company, a program supported by the Ministry of Economy, Trade and Industry of Japan (METI) to empower Japan’s startup ecosystem. For more information, please refer to the following URL. https://www.meti.go.jp/press/2023/04/20230406003/20230406003.html https://www.meti.go.jp/policy/newbusiness/j-startup2023.pdf <About “J-Startup” program> “J-Startup” was launched in ...continuedModulus Discovery, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
News -
13 December, 2022 -
Modulus Discovery, Inc. (“Modulus”), a preclinical stage technology-driven drug discovery company, will present at the 41st Annual J.P. Morgan Healthcare Conference. The J.P. Morgan Healthcare Conference, the largest and most informative healthcare investment symposium in the industry, will be held in San Francisco on January 8-12, 2023. Roy Kimura, Modulus co-founder and CEO, will present ...continued